GENELUX CORPORATION
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.genelux.com
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Phase 2
Recruiting
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer RecurrentMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT06463665
- Locations
- ๐บ๐ธ
Gabrail Cancer and Research Center, Canton, Ohio, United States
๐บ๐ธClermont Oncology Center, Clermont, Florida, United States
๐บ๐ธUniversity of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3
Recruiting
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrioid Ovarian CancerHigh-grade Serous Ovarian CancerOvarian Clear Cell Carcinoma
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05281471
- Locations
- ๐บ๐ธ
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
๐บ๐ธUniversity of Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธCity of Hope, Duarte, California, United States
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
- Conditions
- Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)Acute Myeloid Leukemia (6 Patients)
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Genelux Corporation
- Registration Number
- NCT03420430
- Locations
- ๐บ๐ธ
Florida Hospital Cancer Institute, Orlando, Florida, United States
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Phase 1
Completed
- Conditions
- Peritoneal CarcinomatosisFallopian Tube CancerOvarian Cancer
- Interventions
- Biological: GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT02759588
- Locations
- ๐บ๐ธ
Gynecologic Oncology Associates, Newport Beach, California, United States
๐บ๐ธAdventHealth Cancer Institute, Orlando, Florida, United States
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
Phase 1
Completed
- Conditions
- Cancer of Head and Neck
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT01584284
- Locations
- ๐บ๐ธ
Moores UC San Diego Cancer Center, La Jolla, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath